Prognostic classification factors associated with development of multiple autoantibodies, dysglycemia, and type 1 Diabetesd - A recursive partitioning analysis

Diabetes Care

Volumn 39, Issue 6, 2016, Pages 1036-1044

  Xu, Ping ^a   Krischer, Jeffrey P ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; CATION TRANSPORT PROTEIN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; HLA DQ ANTIGEN; HLA-DQA1 ANTIGEN; HLA-DQB1 ANTIGEN; ICA512 AUTOANTIBODY; INSULIN; PANCREAS ISLET CELL ANTIBODY; SLC30A8 PROTEIN, HUMAN;

ADOLESCENT; AGE; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DYSGLYCEMIA; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; ADULT; CHILD; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; GENETICS; IMMUNOLOGY; METABOLISM; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AUTOANTIBODIES; C-PEPTIDE; CATION TRANSPORT PROTEINS; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; GENOTYPE; GLUCOSE METABOLISM DISORDERS; GLUTAMATE DECARBOXYLASE; HLA-DQ ALPHA-CHAINS; HLA-DQ BETA-CHAINS; HUMANS; INSULIN; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84971282274     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2292     Document Type: Article

References (30)

1. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360-1368
2. Lipton RB, Atchison J, Dorman JS, et al. Genetic, immunological, and metabolic determinants of risk for type 1 diabetes mellitus in families. Diabet Med 1992;9:224-232
3. Harrison LC. Risk assessment, prediction and prevention of type 1 diabetes. Pediatr Diabetes 2001;2:71-82
4. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229
5. Eisenbarth GS. Prediction of type1 diabetes: the natural history of the prediabetic period. In Immunology of Type 1 Diabetes, 2nd ed. Eisenbarth GS, Ed. NewYork, Springer Publishing, 2004, p. 268-281
6. Orban T, Sosenko JM, Cuthbertson D, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:2269-2274
7. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69-82
8. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964-1974
9. Krischer JP; Type 1 Diabetes TrialNet Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 2013;56:1919-1924
10. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10: 97-104
11. Mychaleckyj JC, Noble JA, Moonsamy PV, et al.; T1DGC. HLA genotyping in the international Type 1 Diabetes Genetics Consortium. Clin Trials 2010;7(Suppl.):S75-S87
12. Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. J Clin Endocrinol Metab 2010;95:3360-3367
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(Suppl. 1):S81-S90
14. Ciampi IA, Thiffault J. Recursive partition and amalgamation (RECPAM) for censored survival data: criteria for tree selection. Stat Softw Newsletter 1988;14:78-81
15. Gordon L, Olshen RA. Tree-structured survival analysis. Cancer Treat Rep 1985;69:1065-1069
16. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Belmont, CA, Wadsworth International Group, 1984
17. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York, Wiley, 1987
18. Vehik K, Fiske SW, Logan CA, et al.; TEDDY Study Group. Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY. Diabetes Metab Res Rev 2013;29:557-567
19. Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comp Graph Stat 2006;15:651-674
20. Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP; DPT-1 Study Group. Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care 2012;35:1975-1980
21. Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP; DPT-1 Study Group. Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes. Diabetes Care 2014;37:1959-1965
22. Ziegler AG, Bonifacio E; BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012;55:1937-1943
23. Parikka V, Näntö-Salonen K, Saarinen M, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012;55:1926-1936
24. Krischer JP, Lynch KF, Schatz DA, et al.; TEDDY Study Group. The 6 year incidence of diabetesassociated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015; 58:980-987
25. Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia 2016;59:542-549
26. Sosenko JM, Palmer JP, Greenbaum CJ, et al.; Diabetes Prevention Trial-Type 1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial- Type 1. Diabetes Care 2007;30: 38-42
27. Sosenko JM, Krischer JP, Palmer JP, et al.; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care 2008; 31:528-533
28. Sosenko JM, Skyler JS, Mahon J, et al.; TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The Validation of the Diabetes Prevention Trial-Type 1 risk score and the Detection of Pre-Diabetes in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787
29. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004;53:384-392
30. Sosenko JM, Skyler JS, Palmer JP, et al.; Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups. A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care 2011;34:2435-2437